タイトル(掲載誌)EXPERT OPINION ON THERAPEUTIC TARGETS
一般注記type:text
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder.Despite this, there are no drugs for preventing the onset of AD. Preclinical studies suggest thatinteraction between amyloid-β peptides (Aβ) and the α7 nicotinic acetylcholine receptor (α7nAChR) plays a key role in AD pathology, and that α7 nAChR agonists could act as potentialtherapeutic drugs for AD. A recent study demonstrated that tropisetron, a potent α7 nAChRagonist and serotonin 5-HT3 receptor antagonist, also bound to the ectodomain of amyloidprecursor protein (APP). Furthermore, tropisetron promoted greater improvements in memorythan current AD therapeutic drugs, such as memantine and donepezil. Positron emissiontomography studies detected Aβ deposition and inflammation in the brains of subjects withamnestic mild cognitive impairment (MCI) before the onset of AD. Given the role of α7nAChR in Aβ deposition and inflammation, tropisetron represents an attractive potentialtherapeutic drug to delay or prevent MCI and AD. Additionally since this drug is usedinternationally to treat chemotherapy-induced emesis, its safety record is already known.
一次資料へのリンクURLhttps://opac.ll.chiba-u.jp/da/curator/900118204/20150130_HASHIMOTO-2.pdf
関連情報(DOI)10.1517/14728222.2014.983901
連携機関・データベース国立情報学研究所 : 学術機関リポジトリデータベース(IRDB)(機関リポジトリ)